Lineage Cell Therapeutics Inc (LCTX) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.02 (-0.97%), Market cap $0.32B, 52-week low–high $0.65 ~ $1.96.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensor
Financial statements, price targets, institutional (13F) holdings and related news for Lineage Cell Therapeutics Inc are updated in real time on BlackAll Trade.
Lineage Cell Therapeutics Inc trades at $1.02 (-0.97%). Real-time quotes and charts are available on BlackAll Trade.
Lineage Cell Therapeutics Inc has a market cap of about $0.32B.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company